Research Article
The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C
Table 2
Variable associations with SVR.
| | SVR () | Response failure () | values |
| Gender (males%) | 145 (57.8) | 52 (49.5) | 0.154 | Age ≥ 40 years (%) | 123 (49.60) | 80 (77.7) | <0.001 | IVDU (%) | 95 (37.8) | 16 (15.4) | <0.001 | Alcohol abuse (%) | 27 (11.2) | 14 (14.1) | 0.442 | BMI (kg/m2) | | | 0.035 | Overweight (%) | 24 (28.6) | 25 (50.0) | 0.013 | Genotype distribution | | | <0.001 | Genotype 1 | 111 (45.5) | 53 (52.5) | | Genotype 2 | 17 (7.0) | 6 (5.9) | | Genotype 3 | 98 (40.2) | 15 (14.9) | | Genotype 4 | 18 (7.4) | 27 (26.7) | | High viral load (%) | 39 (40.6) | 28 (45.8) | 0.515 | Abnormal ALT (%) | 236 (96.7) | 95 (95.0) | 0.447 | Abnormal AST (%) | 199 (86.1) | 77 (86.5) | 0.931 | Hepatic steatosis (%) | 64 (25.7) | 49 (46.7) | <0.001 | Severe inflammation (%) | 9 (3.8) | 8 (8.5) | 0.080 | Advanced fibrosis (%) | 26 (10,5) | 30 (28,6) | <0.001 | Cirrhosis (%) | 7 (2,8) | 14 (13,3) | <0.001 | Type of IFN | | | 0.987 | PegIFNα-2a (%) | 69 (28.6) | 27 (28.7) | | PegIFNα-2b (%) | 172 (71.4) | 67 (71.3) | | Dosage adherence (%) | 173 (80.8) | 60 (82.2) | 0.799 |
|
|